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Abstract
Due to the lack of a specific diagnostic tool for neuropathic pain, a grading system to categorize pain as ‘definite’,
‘probable’, ‘possible’ and ‘unlikely’ neuropathic was proposed. Somatosensory abnormalities are common in neuropathic
pain and it has been suggested that a greater number of abnormalities would be present in patients with ‘probable’ and
‘definite’ grades. To test this hypothesis, we investigated the presence of somatosensory abnormalities by means of
Quantitative Sensory Testing (QST) in patients with a clinical diagnosis of neuropathic pain and correlated the number of
sensory abnormalities and sensory profiles to the different grades. Of patients who were clinically diagnosed with
neuropathic pain, only 60% were graded as ‘definite’ or ‘probable’, while 40% were graded as ‘possible’ or ‘unlikely’
neuropathic pain. Apparently, there is a mismatch between a clinical neuropathic pain diagnosis and neuropathic pain
grading. Contrary to the expectation, patients with ‘probable’ and ‘definite’ grades did not have a greater number of
abnormalities. Instead, similar numbers of somatosensory abnormalities were identified for each grade. The profiles of
sensory signs in ‘definite’ and ‘probable’ neuropathic pain were not significantly different, but different from the ‘unlikely’
grade. This latter difference could be attributed to differences in the prevalence of patients with a mixture of sensory gain
and loss and with sensory loss only. The grading system allows a separation of neuropathic and non-neuropathic pain based
on profiles but not on the total number of sensory abnormalities. Our findings indicate that patient selection based on
grading of neuropathic pain may provide advantages in selecting homogenous groups for clinical research.
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Introduction
The International Association for the Study of Pain (IASP)
defined neuropathic pain as a direct consequence of a lesion or
disease affecting the somatosensory system [1]. Neuropathic pain
has traditionally been classified based on the underlying aetiology
[2]; [3]; [4]. Due to the lack of a specific diagnostic tool for
neuropathic pain, a grading system of ‘definite’, ‘probable’,
‘possible’ and ‘unlikely’ neuropathic pain was proposed [1]. This
grading system aims to determine with a greater level of certainty
whether a pain condition is neuropathic, especially relevant when
including patients in clinical trials. Briefly, the grade ‘unlikely’ is
applicable when patients lack a history of a lesion or disease with a
plausible neuroanatomical distribution of their pains. The grade
‘possible’ could be regarded as a working hypothesis, which does
not exclude, neither diagnoses neuropathic pain. Patients who fall
into the category ‘possible’ neuropathic pain can be transferred
into the grades ‘probable’ and ‘definite’ if neurologic examination
and the presence of a positive confirmatory test reveal confirma-
tory evidence. Only the grades ‘probable’ and ‘definite’ indicate
neuropathic pain.
Although the proposed grading system is intended for clinical
and research purposes and has been available for several years,
large cohort studies comparing somatosensory function of
clinically diagnosed neuropathic pain patients and patients
categorized according to the new grading system are not available.
As the neuropathic pain is characterized by both, positive and
negative sensory phenomena, it is critical for those phenomena to
be captured and, for their optimal utility, to be measured
quantitatively. Screening tools for neuropathic pain have been
recommended by the NeuPSIG guidelines and include the LANSS
and S-LANSS, the NPQ, the DN4, painDETECT and ID-
Pain18. Since 10–20% of patients with neuropathic pain will not
be detected by these questionnaires it is obvious that these
questionnaires cannot replace clinical examination and judgement
[5]. Thus, clinical examination is a crucial part of the diagnostic
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process in neuropathic pain, with sensory testing being the most
important factor [5].
The German Research Network on Neuropathic Pain (DNFS)
established a standardized Quantitative Sensory Testing (QST)
protocol which allows a comprehensive somatosensory character-
isation of chronic neuropathic pain patients, using reference values
from healthy volunteers [6,7]. This protocol uses 13 different
mechanical and thermal stimuli (e.g. graded von Frey filaments,
pin-prick devices, a pressure algometer, and quantitative thermo-
testing). It takes about 30 minutes to test one location of the body
in healthy volunteers and about 45 minutes in patients. This QST
battery tests different sub-modalities of nerve fibres involved in the
transduction of sensory information from the periphery to the
spinal cord such as Ab-fibre, Ad-fibre and C-fibre [6,7].
There is a long tradition of quantitative measurement of somatic
sensory function, well documented in a number of publications
[8,9,10,11] and it has been shown to be adequate with respect to
reliability and validity [12]. Several publications show that also
QST is valid, reliable and sensitive to quantify sensory abnormal-
ities [13,14,15,16].
The ultimate goal of identifying differences in the response to
sensory stimuli in neuropathic pain patients is the identification of
differences in the mechanisms responsible for generating sensory
abnormalities and their subsequent mechanism-based therapy. A
recent QST study showed that specific profiles (along thirteen
different QST parameters) correspond to the different clinical
entities of neuropathic pain [16]. The authors hypothesized that in
case of a patient showing many sensory abnormalities, the grading
of this patient would fulfil the criteria for ‘probable’ or ‘definite’
neuropathic pain.
Previously, we showed that bilateral somatosensory abnormal-
ities were common in patients with unilateral neuropathic pain
[17]. We did not account differences in the numbers of sensory
abnormalities at the affected side between the clinical entities of
neuropathic pain of our study population. In the present study, we
hypothesized that the number of somatosensory abnormalities in
patients with clinically diagnosed neuropathy do not differ within
the ‘definite’, ‘probable’, ‘possible’ and ‘unlikely’ neuropathic pain
grading groups. We also aimed to find QST profile-based
corroboration for the new grading system.
We selected a large cohort of patients with clinically confirmed
neuropathic pain and subsequently categorized each patient
according to the neuropathic pain grading. We examined the
painful area using the standardized German Research Network on
Neuropathic Pain (DNFS) QST protocol comparing patient values




The study adhered to the declaration of Helsinki and was
approved by the independent, medical ethical committee ‘‘Sticht-
ing Beoordeling Ethiek Bio-Medisch Onderzoek’’, P.O. Box 1004,
9400 BA Assen, The Netherlands. This committee is acknowl-
edged by the Central Committee on Research Involving Human
Subjects (known by its Dutch initials, CCMO). Patients and
healthy controls were recruited from the local region. All
participants signed an informed consent form.
Description of Healthy Controls
Healthy subjects were recruited by advertisement in the local
newspaper and were identified according to medical history.
Subjects were specifically questioned regarding previous injuries or
diseases. The healthy subjects did not use analgesics regularly and
were free of medication at the time of the assessments. In total, 209
age- and gender-matched healthy volunteers (age range 20–73
years), of which 138 females (age 45.3613.4 years) and 71 males
(age 48.7614.0 years) underwent QST assessments on both, the
dorsal hand and foot. These body locations have been proposed as
reference sites for QST [6]. Since there are no significant
differences in QST parameters between the right and left sides
of the body in healthy volunteers [6], we obtained QST reference
values from one side of the body. In total, 418 QST references
from the upper and the lower extremity were obtained.
Description of the Patient Cohort
Patients with neuropathic pain lasting for more than three
months were recruited from the outpatient Department of the
Pain Management Unit of the University Medical Center
Groningen, The Netherlands. Patients were diagnosed with
neuropathic pain by the physicians of the Unit. Neuropathic pain
diagnosis was made based on coherent patient history, medical
history and physical examination which included neurological
function tests. Each clinical diagnosis was additionally confirmed
by an experienced pain specialist of the Pain Management Unit
based on patient’s files. In total, 84 neuropathic pain patients (age
51.7 year, range 22–75 years), of which 46 females (age 51.4612.7
years) and 38 males (age 52.0612.8 years) were assessed. Prior to
the QST assessments, patients were asked to rate their ongoing
pain level using a Numerical Rating Scale (NRS) of ‘0’ indicating
‘‘no pain’’, and ‘100’ indicating ‘‘most intense pain imaginable’’.
Patients did not discontinue their regular pain treatment if
applicable. Patients underwent the QST assessment, at the area
where the most profound pain was experienced (leg: n= 59, arm:
n= 25).
Quantitative Sensory Testing (QST)
The QST battery consisted of seven tests, measuring thirteen
parameters and was applied according to the standardized
protocol [6]. QST was performed by two research nurses, who
underwent a comprehensive training at the DNFS in Germany.
All tests were performed at the same research facility of PRA Int.,
Groningen, The Netherlands. The average room temperature was
23.1uC 61.7uC.
Thermal QST tests were performed using the Pathway System
(Medoc, Israel)andconsistedofsixparameters: thresholdassessments
for warm and cold detection (WDT, CDT) and heat pain and cold
pain (HPT,CPT). Inaddition, subjectswereaskedaboutparadoxical
heat sensations (PHS) during the thermal sensory limen (TSL)
procedure of alternating warm and cold stimuli.
Mechanical QST tests consisted of seven different parameters.
The mechanical detection threshold (MDT) was determined with
modified von Frey filaments (Optihair2-Set, Marstock Nervtest,
Germany). The mechanical pain threshold (MPT) was measured
with seven weighted pinprick devices (cylindrical, 0.2 mm in
diameter flat contact area) with fixed stimulus intensities forces of
8, 16, 32, 64, 128, 256, and 512 mN. Mechanical pain sensitivity
(MPS) was assessed using the same pinprick devices to obtain a
stimulus–response relation. Dynamic mechanical allodynia (DMA)
was assessed as part of the test above, using a set of three light
tactile stimulators as dynamic innocuous stimuli: cotton wisp,
cotton wool tip fixed to an elastic strip and a standardized brush
(SENSElab No. 5, Somedic, Sweden). Vibration detection
threshold (VDT) was performed with a Rydel–Seiffer graded
tuning fork (64 Hz, 8/8 scale) that was placed over a bony
prominence. The wind up ratio (WUR) test was assessed with a
pinprick intensity of 256 mN. The pressure pain threshold (PPT)
QST and Neuropathic Pain Grading
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was determined over muscle with a pressure gauge device
(FDN200, Wagner Instruments, CT, USA).
Neuropathic Pain Grading
For each of the neuropathic pain patients the diagnosis of
neuropathic pain was confirmed using the grading system that
categorizes neuropathic pain as ‘‘definite’’, ‘‘probable’’, ‘‘possible’’
or ‘‘unlikely’’ neuropathic pain [1]. If a patient’s pain complaints
did not have a plausible neuroanatomical distribution and lack a
history which suggests a relevant lesion or disease, they were
regarded as ‘unlikely’ neuropathic. If both requirements were
fulfilled the working hypothesis ‘possible’ neuropathic pain was
applied. If confirmatory tests such as positive or negative sensory
signs confined to the innervations area of the relevant nerve
structure and a diagnostic test confirming the lesion or disease
were both positive, patients were graded as ‘definite’ neuropathic
pain. In case of only one positive confirmatory test, a patient’s pain
was graded as ‘probable’ neuropathic. If both confirmatory tests
were inconclusive or not performed, a patient’s pain was regarded
as unconfirmed and patients were assigned ‘possible’ neuropathic
pain. All patients in the present study were allocated to one of the
four neuropathic pain grades.
Z-transformation of QST Data
QST data of patients with neuropathic pain were compared
with reference data from gender and age matched healthy
volunteers. Since the response to the different QST parameter
can be subject to changes over age [6,7,16,18] we divided both,
patients and healthy subjects into three age groups each (20–45
years of age, 46–60 years of age and 61–75 years of age). QST
values of chronic pain locations on the upper extremities were
compared to QST reference values obtained from the dorsal hand
of healthy controls (n = 63 for females and n= 29 for males for age
group 20–45 years; n = 58 for females and n= 24 for males for age
group 46–60 years; n = 17 for females and n= 18 for males for age
group 61–75), whereas values from chronic pain locations on
lower extremities were compared to reference values obtained
from the dorsal foot of healthy controls (n = 63 for females and
n=29 for males for age group 20–45 years; n = 58 for females and
n=24 for males for age group 46–60 years; n = 17 for females and
n=18 for males for age group 61–75). QST values from each
patient were transformed to z-scores as described by Rolke et al.,
2006 [6]. A score above 1.96 or below 21.96 falls outside the 95%
confidence interval of the mean reference value and was
considered as a sensory abnormality. Abnormalities were subse-
quently categorized as either a sensory gain or a sensory loss.
As it never occurs in healthy volunteers that dynamic innocuous
stimuli are experiences as painful, the QST parameter ‘‘dynamic
mechanical allodynia’’ (DMA) could not be used for z-score
analyses. In this case, ratings greater than NRS 10 (scale 0–100)
were regarded as clinically relevant and identified as abnormal.
For the QST parameter ‘‘Wind-Up Ratio’’ (WUR), eighteen
patients rated the single pinprick stimulus as ‘‘0’’ making ratio
calculations (painfulness of one pinprick stimulation vs. painfulness
of a train of ten pinprick stimulations) for Wind-Up impossible.
For these patients WUR was not used for subsequent analyses.
Similar, 31 healthy subjects rated the single pinprick stimulus as
‘‘0’’ making ratio calculations for Wind-up impossible.
Proportions of Sensory Signs for the Different
Neuropathic Pain Grades
Profiles of sensory signs were defined based on the overall
sensory numbers and their representation in sensory loss, sensory
gain, mixture of sensory loss and gain and no sensory abnormal-
ities. To investigate the differences in the proportions of sensory
loss, sensory gain or a mixture of sensory loss and gain for the
different neuropathic pain grades, we calculated the 95%
confidence intervals of the proportions using the ‘Wilson Estimate’
of proportion [19].
Figure 1. Sensory findings for patients according to neuropathic pain grades and healthy controls. Sensory findings (gain and/or loss of
sensory function) in % for healthy controls (n = 209 with 418 test sides), for patients (n = 84) overall and ordered according to their likelihood to be
neuropathic pain. ‘‘No sensory abnormalities’’: none of the Quantitative Sensory Testing (QST) parameters were outside the 95% CI. ‘‘Only sensory
gain’’: at least one QST parameter indicating thermal or mechanical hyperesthesia or hyperalgesia without the presence of hypesthesia or
hypoalgesia. ‘‘Only sensory loss’’: at least one QST parameter indicating thermal or mechanical hypesthesia or hypoalgesia without the presence of
hyperesthesia or hyperalgesia. ‘‘Sensory gain and loss’’: at least one positive sign combined with one negative sign. Wilson estimates of proportions
between the groups of definite and probable neuropathic pain and the group of unlikely neuropathic pain for only sensory loss and sensory gain and
loss parameter (*p,0.05).
doi:10.1371/journal.pone.0043526.g001
QST and Neuropathic Pain Grading
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Correlation between the Number of Sensory
Abnormalities and Neuropathic Pain Grades
For each grading, numbers of sensory abnormalities were
compared using ANOVA. The total numbers of sensory gain and
sensory loss as well as the overall numbers of sensory abnormalities
across the thirteen QST parameters were correlated to the
different neuropathic pain grades using Spearman correlations.
Correlation between Background Pain and Neuropathic
Pain Grades
For each grading, background pain intensities were compared
using ANOVA. To identify a possible relationship between
neuropathic pain grade and background pain, Pearson correlation
was used. P-values ,0.05 were regarded as significant for each
statistical test performed.
Results
QST Observations in Healthy Controls
From the healthy control cohort (n = 209) investigated in this
study, a total of 418 locations were assessed and 5403 measure-
ments were analysed by means of z-score profiling. The total of
1412 measurements for the most affected area were analysed by
means of z-score profiling.
Sensory Abnormalities in Healthy Controls
Although the majority of the QST results obtained in healthy
controls confirmed normal sensory function for this cohort,
incidental sensory abnormalities (4.3%) were observed for all
QST parameters with the exception of DMA. Out of the total of
418 different body areas that were tested across all healthy controls
62% (259 locations) showed normal sensory function and 38%
(159 locations) showed a sensory abnormality for at least one QST
parameter. Sensory abnormalities were regarded as sensory gain in
21%, sensory loss in 13% and a mixture of sensory gain and
sensory loss in 4% of the cases (Fig. 1).
Demographics of Patients
Demographic data of the patients are shown in Table 1. Apart
from two patients, all patients reported ongoing spontaneous pain
ranging from 3 to 100 (Mean 63.2622.2 SD) on a 0–100 NRS just
before the QST assessment took place.
Clinical Diagnosis of Neuropathic Pain
The aetiology of patient’s pain in our sample was diverse. The
largest subgroup developed pain after a surgical intervention (20)
followed by patients who had a trauma (16). Other causes of pain
were polyneuropathy (12), failed back surgery (10), pain after
fracture (6), Herniated Nucleus Pulposus (HNP) (4), spinal cord
injury (3), peripheral nerve entrapment (3), central pain (3),
amputation (3), Radiotherapy (2), and pain after infection (2). The
clinical diagnoses of patients included peripheral nerve injury (63),
polyneuropathy (14), spinal cord injury (3), central pain (3) and
complex regional pain syndrome (CRPS) (1) (see Table 1).
Grading of Neuropathic Pain
Patient’s pain was graded into ‘definite neuropathic’ (n = 25),
‘probable neuropathic’ (n = 31), ‘possible neuropathic’ (n = 4) and
‘unlikely neuropathic’ (n = 24) according to the classification by
Treede and colleagues [1]. Thus, of the 84 neuropathic pain
patients investigated, 67% were graded as having ‘definite’ and
‘probable’ neuropathic pain. Out of this group 45% were
accounted as ‘definite’ neuropathic. For patients graded as
‘probable’ neuropathic pain, 65% (n= 20) a diagnostic test was
not performed and 35% (n= 11) had a negative outcome of the
diagnostic test. Interestingly, in one patient with ‘probable’
neuropathic pain grading the diagnostic test was positive but the
confirmatory test was negative (Table 1).
All four patients graded as ‘possible’ neuropathic pain did not
have their sensory signs in a neuroanatomical confined territory.
For this patient group more confirmatory and diagnostic work
would be necessary to advance this group to ‘probable’
neuropathic pain. 30% of the clinically diagnosed neuropathic
pain patients were graded as ‘unlikely’ neuropathic pain. This was
due to the fact that there was a lack of history of patient’s lesion or
disease and their pain complaints were not in a plausible
neuroanatomical distribution (Table 1).
Sensory Abnormalities in Neuropathic Pain
For the 84 patients investigated in this study, 1092 QST data
measurements were obtained. In patients with neuropathic pain,
sensory abnormalities were observed in all QST parameters. In
our patient cohort, 93% had at least one QST abnormality. From
these patients 54% had a mixture of sensory gain and loss, 20%
had only sensory gain (hyperalgesia) and 19% had only sensory
loss (hypesthesia) (Fig. 1).
Proportions of Sensory Signs for the Different
Neuropathic Pain Grades
The profiles of sensory signs in ‘definite’ and ‘probable’
neuropathic pain were not significantly different, but different
from the ‘unlikely’ grade. This latter difference was due to an
increase of a mixture of sensory gain and loss and a decrease in
frequency of sensory loss only for the ‘unlikely’ grade compared to
the ‘definite’ and ‘probable’ neuropathic pain grade (all p,0.05)
(Fig. 1).
These results indicate that profiles of sensory signs for ‘definite’
and ‘probable’ neuropathic pain differ from the profiles for the
‘unlikely’ grade.
Individual QST Parameters
For the different grading groups of neuropathic pain similar
patterns of the distribution of sensory abnormalities were
observed. Since the different neuropathic pain grades showed
comparable profile only the two most distant opponents i.e.
‘definite’ and ‘unlikely’ neuropathic pain, are displayed for
illustration in Figure 2. All neuropathic pain grades showed
predominantly sensory gain changes for nociceptive QST param-
eters (CPT, HPT, PPT, MPS, WUR) reflecting hyperalgesia,
whereas the non-nociceptive parameters (CDT, WDT, TSL,
MDT, VDT) reflected hypesthesia (Fig. 2). For the nociceptive
parameters CPT and HPT, thermal pain thresholds were
decreased indicating thermal hyperalgesia. An increased pain
due to blunt pressure (PPT) and an increased sensitivity to
mechanical pain (MPS) were observed indicating only hyperalge-
sia for these parameters. For MPT a greater incidence for
mechanical hypo- than hypersensitivity was detected. WUR was
always increased and not decreased indicating hypersensitivity.
For every patient sensory loss was only observed for the non-
nociceptive CDT indicating a thermal hypesthesia. In addition,
thermal hypesthesias were observed in most of the patients for
WDT and TSL. For MDT predominantly a sensory loss was
observed indicating a mechanical hypesthesia. It was not possible
to detect hyperesthesia for VDT as the maximal value of 8/8
measured by the tuning fork was within the normal range. PHS
QST and Neuropathic Pain Grading
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1 M 62 50 Polyneuropathy polyneuropathy yes yes yes positive definite NP 3
2 F 43 60 Post stroke pain central pain yes yes yes positive definite NP 6
3 M 52 75 Spinocerebellar
ataxia
central pain yes yes yes positive definite NP 6
4 F 57 80 Diabetic
polyneuropathy
polyneuropathy yes yes yes positive definite NP 1




yes yes yes positive definite NP 2
6 F 53 50 TH12 fracture spinal cord injury yes yes yes positive definite NP 4
7 F 52 80 Sepsis and organ
failures
polyneuropathy yes yes yes positive definite NP 5
8 F 71 60 Failed back surgery peripheral nerve
injury
yes yes yes positive definite NP 4




yes yes yes positive definite NP 4
10 F 72 50 Failed back surgery peripheral nerve
injury
yes yes yes positive definite NP 0
11 M 41 60 Failed back surgery peripheral nerve
injury
yes yes yes positive definite NP 3




yes yes yes positive definite NP 4
13 F 43 80 Postsurgical pain CRPSII yes yes yes positive definite NP 5
14 M 53 70 Polyneuropathy polyneuropathy yes yes yes positive definite NP 6




yes yes yes positive definite NP 5
16 M 52 75 Myelopathy spinal cord injury yes yes yes positive definite NP 3
17 M 46 0 Cruris fracture peripheral nerve
injury
yes yes yes positive definite NP 4
18 M 66 75 Polyneuropathy polyneuropathy yes yes yes positive definite NP 1




yes yes yes positive definite NP 0




yes yes yes positive definite NP 4




yes yes yes positive definite NP 5




yes yes yes positive definite NP 1
23 F 43 100 Cervical myelopathy peripheral nerve
injury
yes yes yes positive definite NP 6




yes yes yes positive definite NP 3
25 M 46 65 Failed back surgery peripheral nerve
injury
yes yes yes positive definite NP 2
26 F 37 90 Postsurgical pain peripheral nerve
injury
yes yes yes none probable NP 4




yes yes yes negative probable NP 0




yes yes yes negative probable NP 1
29 M 56 80 Postsurgical pain peripheral nerve
injury
yes yes yes none probable NP 5




yes yes yes none probable NP 4
31 F 53 80 Radiotherapy peripheral nerve
vinjury
yes yes yes none probable NP 3
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yes yes yes none probable NP 4
33 F 56 3 Postsurgical pain peripheral nerve
injury
yes yes yes none probable NP 2
34 F 59 60 Postsurgical pain peripheral nerve
injury
yes yes yes none probable NP 4




yes yes yes none probable NP 3
36 F 41 70 Postsurgical pain peripheral nerve
injury
yes yes yes negative probable NP 5
37 F 66 70 Postsurgical pain peripheral nerve
injury
yes yes no positive probable NP 2
38 M 40 60 Amputation peripheral nerve
injury
yes yes yes negative probable NP 2
39 F 62 80 Failed back surgery peripheral nerve
injury
yes yes yes none probable NP 5
40 F 46 85 Postsurgical pain peripheral nerve
injury
yes yes yes negative probable NP 2
41 F 54 65 Diabetic
polyneuropathy
polyneuropathy yes yes yes none probable NP 4
42 F 46 40 Amputation peripheral nerve
injury
yes yes yes none probable NP 3
43 M 63 80 Postsurgical pain peripheral nerve
injury
yes yes yes negative probable NP 1




yes yes yes negative probable NP 4
45 F 27 70 Femur fracture peripheral nerve
injury
yes yes yes negative probable NP 8




yes yes yes negative probable NP 1
47 M 58 80 Postsurgical pain peripheral nerve
injury
yes yes yes negative probable NP 0
48 F 58 90 Postsurgical pain peripheral nerve
injury
yes yes yes none probable NP 3
49 F 41 70 Metacarpal fracture peripheral nerve
injury
yes yes yes none probable NP 2
50 M 57 75 Tibia fracture peripheral nerve
injury
yes yes yes none probable NP 6
51 M 57 40 Polyneuropathy polyneuropathy yes yes yes none probable NP 6
52 M 73 70 Polyneuropathy polyneuropathy yes yes yes none probable NP 0
53 M 24 50 Postsurgical pain peripheral nerve
injury
yes yes yes none probable NP 9
54 F 61 20 Diabetic
polyneuropathy
polyneuropathy yes yes yes none probable NP 3
55 F 75 50 Failed back surgery peripheral nerve
injury
yes yes yes negative probable NP 5
56 F 44 45 Postsurgical pain peripheral nerve
injury
yes yes yes none probable NP 4
57 M 47 50 Postsurgical pain peripheral nerve
injury
yes yes no none possible NP 4
58 M 51 70 Postsurgical pain peripheral nerve
injury
yes yes no none possible NP 6




yes yes no negative possible NP 2
60 F 52 100 Failed back surgery peripheral nerve
injury
yes yes no none possible NP 5
QST and Neuropathic Pain Grading
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and DMA were found to be increased within all grading of
neuropathic pain.
Our results show that sensory abnormalities for the individual
QST parameters are remarkably similar between the grades of
neuropathic pain. These similarities were also reflected in the
distribution for nociceptive and non-nociceptive QST parameters
for the different neuropathic pain grades.
Number of Sensory Abnormalities in Relation to
Neuropathic Pain Grading
The number of sensory abnormalities in neuropathic pain
patients varied between 0 and 9 for the thirteen QST parameters
(see Table 1). In three out of the four grading categories, i.e.
























yes no yes negative unlikely NP 6




yes no yes none unlikely NP 1
63 M 75 65 Postsurgical pain peripheral nerve
injury
no yes no none unlikely NP 2
64 M 54 75 Postsurgical pain peripheral nerve
injury
no yes no none unlikely NP 3
65 F 59 75 Ischemic CVA central pain yes no no none unlikely NP 0
66 M 37 60 Accident with
trauma
spinal cord injury no yes no negative unlikely NP 4
67 F 65 50 Amputation peripheral nerve
injury
no yes no negative unlikely NP 4
68 M 59 55 Borrelia infection polyneuropathy no yes no none unlikely NP 2
69 F 36 70 Cruris fracture peripheral nerve
injury
no no no none unlikely NP 8
70 M 51 80 Failed back surgery peripheral nerve
injury
no no no negative unlikely NP 4
71 F 39 80 Postsurgical pain peripheral nerve
injury
no no no none unlikely NP 4
72 M 42 70 Failed back surgery peripheral nerve
injury
no no no none unlikely NP 2




no no no none unlikely NP 2
74 F 66 90 Postsurgical pain peripheral nerve
injury
no no no none unlikely NP 5
75 M 71 20 Polyneuropathy polyneuropathy no no no none unlikely NP 7




no no no none unlikely NP 3
77 F 22 0 Postsurgical pain peripheral nerve
injury
no no no none unlikely NP 4




no no no negative unlikely NP 2
79 F 50 10 Radiotherapy peripheral nerve
injury
no no no none unlikely NP 1
80 F 75 90 Polyneuropathy polyneuropathy no no no positive unlikely NP 7




no no no negative unlikely NP 7
82 M 62 80 Polyneuropathy polyneuropathy no no no none unlikely NP 2
83 F 49 30 Failed back surgery peripheral nerve
injury
no no no negative unlikely NP 4
84 M 57 50 Polyneuropathy polyneuropathy no no no negative unlikely NP 2
Demographic patient overview; Patient ID, gender and age are indicated. Patient’s rating of ongoing pain prior to Quantitative Sensory Testing (QST) using a Numeric
Rating scale (NRS) indicating ‘‘0’’ as ‘‘no pain’’ and ‘‘100’’ as the ‘‘most intense pain imaginable’’. Cause of pain and clinical diagnosis is indicated. For allocating patients
pain complaints as neuropathic pain a grading system was applied [1]. This grading determine with a greater level of certainty whether a pain condition is neuropathic.
To increase likelihood of neuropathy grading requires that pain in plausible neuroanatomical distribution (Grading 1), that there is a history for a lesion or disease
(Grading 2), sensory signs are in a neuroanatomical plausible distribution (Grading 3) and the presence of a positive confirmatory test (Grading 4) (none indicates that
no test was performed). Number of abnormalities refers to the number of QST parameter exceeding CI 95% of z-scores at the affected side.
doi:10.1371/journal.pone.0043526.t001
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fraction of patients did not show any sensory abnormality upon
undergoing the complete QST monitoring.
When comparing the number of sensory abnormalities in the
different categories of graded patients, the mean number of
abnormalities for the group of patients graded as ‘definite’
neuropathic pain was 3.5 (SD 61.9). Similar numbers were also
found for the group of patients with ‘probable’ and ‘unlikely’
neuropathic pain, 3.4 (SD 62.2) and 3.6 (SD 62.1) respectively.
Figure 2. QST z-score abnormalities for patients graded as ‘definite’ and ‘unlikely’ neuropathic pain. Quantitative Sensory Testing (QST)
z-score abnormalities in % for ‘definite’ neuropathic pain (top) and ‘unlikely’ neuropathic pain (bottom) grades. QST parameter are ordered as sensory
parameters: Cold Detection Threshold (CDT), Warm Detection Threshold (WDT), Thermal Sensory Limen (TSL), Mechanical Detection Threshold (MDT),
Vibration Disappearance Threshold (VDT), Paradoxical Heat Sensation (PHS), Dynamic Mechanical Allodynia (DMA) and nociceptive parameters: Cold
Pain Threshold (CPT), Heat Pain Threshold (HPT), Pressure Pain Threshold (PPT), Mechanical Pain Threshold (MPT), Mechanical Pain Sensitivity (MPS)
and Wind Up Ratio (WUR). Z-scores with positive sensory signs (gain of sensory function) plotted upwards and negative sensory signs (loss of sensory
function) plotted downwards. Absence of DMA is normal and therefore no negative sign possible.
doi:10.1371/journal.pone.0043526.g002
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Slightly higher was the number of abnormalities observed for the
group of patients graded as ‘possible’ neuropathic pain (4.3, SD
61.7). This increase is not significant compared to patient groups
graded as ‘definite’, ‘probable’ or ‘unlikely’ neuropathic pain using
ANOVA (Fig. 3). The total numbers of sensory gain and sensory
loss as well as the overall numbers of sensory abnormalities across
the thirteen QST parameters were not correlated to the different
neuropathic pain grades using Spearman correlations.
Background Pain in Relation to Neuropathic Pain Grading
Except for two patients, all patients reported ongoing sponta-
neous pain (NRS mean 63.3, SD622.2) before the QST
assessment took place (see Table 1). For patients graded as
‘definite’ neuropathic pain the mean NRS score for spontaneous
pain were 65.4 (SD620.2). Slightly higher pain levels were
reported by patients graded as ‘possible’ neuropathic pain (70.0,
SD621.6). Patient’s graded as ‘probable’ and ‘unlikely’ reported
slightly lower pain levels of 64.5 (SD620.2) and 58.3 (SD626.3),
respectively. However, these differences were not significant
(ANOVA). Pearson correlation revealed no significant difference
between neuropathic pain grade and background pain.
Discussion
Investigating the somatosensory profiles of patients using QST
showed that somatosensory abnormalities are a common feature in
neuropathic pain. Applying the grading system for neuropathic
pain revealed similar numbers of somatosensory abnormalities
across the four different grading categories. Analysing the profile
of sensory signs showed that overall the ‘definite’ and ‘probable’
neuropathic pain groups have a similar profile. The categories of a
mixture of sensory gain and loss as well as sensory loss only
differed significantly for these groups compared to the ‘unlikely’
grade. There was no significant correlation between background
pain and the different neuropathic pain grades.
The grading system allows a separation of neuropathic and non-
neuropathic pain based on profiles but not on the total amount of
sensory abnormalities. Thus, the suggestion that patient selection
based on grading of neuropathic pain may provide a more
homogenous group of neuropathic pain patients for research and
for clinical studies is only partly supported by the findings of this
study.
Clinical Diagnoses and Grading of Neuropathic Pain
All patients investigated in the present study were diagnosed
with neuropathic pain based on clinical presentation. Neuropathic
pain is notoriously difficult to diagnose and due to the lack of a
specific diagnostic tool a grading system to categorize pain as
‘definite’, ‘probable’, ‘possible’ and ‘unlikely’ neuropathic was
proposed [1]. For 71% of the patients investigated, a direct history
of a relevant lesion or disease and plausibly distributed pain was
confirmed. These patients were subsequently graded at least as
‘possible’ neuropathic pain. In 23% of the patients such a plausible
distribution of their pains was not identified, therefore these
patients were graded as ‘unlikely’. For 25% of the patients no
direct history of a relevant lesion or disease was identified. For
these patients a greater degree of certainty than ‘unlikely’ could
not be reached. Overall, 29% of patients gained the neuropathic
pain grade ‘unlikely’.
A small group of patients (5%) were graded as ‘possible’
neuropathic pain. Here confirmatory tests were either negative or
had not yet been performed, therefore this group of patients is
regarded as having ‘unconfirmed’ neuropathic pain. This status is
difficult to judge since clinical investigations determine this
category. Any additional positive confirmatory test could change
the status to neuropathic pain e.g. ‘probable’ and/or ‘definite’. On
the other hand, it has not been described how to proceed with the
grading if future confirmatory tests were negative. For that reason
the comparison of ‘definite’ and ‘probable’ versus ‘unlikely’
neuropathic pain grading is the most valuable for this paper.
Figure 3. Numbers of sensory abnormalities for patients according to neuropathic pain grades. Numbers of sensory abnormalities
(sensory gain and loss) for patients (n = 84) graded as ‘definite’, ‘probable’, ‘possible’ and ‘unlikely’ neuropathic pain; Mean values 6 SEM.
doi:10.1371/journal.pone.0043526.g003
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According to the classification criteria only definite and
probable grades are to be regarded as neuropathic pain [1].
Therefore, 33% of patients investigated should be regarded as
having non-neuropathic pain. Apparently, there is a mismatch in
the outcome ‘neuropathic pain’ between the clinical observations/
diagnosis and the grading system. Reason for such differences
could lie in the fact that the grading system relies on a direct
relationship between cause of pain and its neuroanatomical
plausible distribution to exclude ‘unlikely’ neuropathic pain grade.
It could be argued that the grading system is ‘‘biased’’ towards
precisely defined neuropathic pain entities. Once a distinct clinical
entity is confirmed an increase in the certainty of neuropathic pain
is almost an ‘‘epiphenomenon’’ since confirmatory evidence is
often part of the assessment. Examples include neuropathic pain
after a known surgical nerve lesion or postherpetic neuralgia after
shingles. From a clinical perspective such a direct relationship is
sometimes difficult to establish. For example, a large group in the
present study are postsurgical pain patients (n = 20) which were
diagnosed clinically with peripheral nerve injury. Out of this pool,
thirteen patients were graded as ‘definite’ and ‘probable’, two
patients as ‘possible’ and five patients as ‘unlikely’ neuropathic
pain. For grading purposes, it has been suggested that the
distribution of pain or hyperalgesia does not necessarily need to be
identical to the innervations area of a peripheral nerve or root, but
it should be in a distribution that is typical for the underlying
disorder [1]. This is easy to recognise in well-defined diseases such
as postherpetic neuralgia where central sensitization might
influence the distribution of sensory abnormalities. In contrast it
is less clear in patients with postsurgical pain since it has been not
established if damage to tissues other than nerves causes
neuropathic pain after surgery [20].
Overall, 67% of the patients were graded as ‘definite’ and
‘probable’ neuropathic pain. Interestingly, different clinical
neuropathic pain entities were found consistently within the
different grades of neuropathic pain.
Somatosensory Function in Healthy Controls
Z-score transformation of QST data revealed one or more
somatosensory abnormalities in 38% of the healthy control group.
This number is in line with previous findings of 41% abnormalities
using the QST protocol [16].
For healthy volunteers, abnormalities were observed across all
QST parameters with the exception of DMA. The detected
sensory abnormalities reflected gain of function for the most part,
some loss of function and in a minority a mixture of gain and loss
of function (Fig. 2).
Somatosensory Function in Neuropathic Pain Patients
As expected, the large majority (93%) of neuropathic pain
patients showed sensory abnormalities. Previously, a similar
percentage (92%) of patients with at least one QST abnormality
were reported [16]. Given the fact that for 7% of the patients, no
abnormality could be detected, QST and the cut-off of 95% CI of
the mean reference values might be more stringent than clinical
examination.
In accordance with previous studies, sensory loss was predom-
inantly found in non-nociceptive parameters [16,21], which could
be associated with central or peripheral neuronal damage leading
to ongoing pain via increased ectopic activity [22,23,24]. Sensory
gain was predominantly found in nociceptive parameters which
could be associated with peripheral sensitization and/or altered
central processing [10,25,26,27,28]. Overall, there was good
agreement between our estimates of the expected range of sensory
abnormalities in the general neuropathic pain patient population
and those reported by Maier [16].
Somatosensory Function Across the Grading of
Neuropathic Pain
The pattern of sensory abnormalities for nociceptive and non-
nociceptive parameters did not differ for the different neuropathic
pain grades. A similar distribution of nociceptive and non-
nociceptive parameters was previously reported in neuropathic
pain patients [16].
Recently, Maier and colleagues reported in a QST study of
1236 neuropathic pain patients that profiles of sensory abnormal-
ities differ in the neuropathic pain conditions [16]. Differences in
profiles of sensory abnormalities were also observed in our study
based on the grading system of neuropathic pain. The presence of
sensory gain and loss and only sensory loss was similar for the
grade of ‘definite’ and ‘probable’ but was significantly different to
the grade ‘unlikely’ neuropathic pain.
Our results indicate that the grading system allows a separation
of neuropathic and non-neuropathic pain based on profiles of
sensory abnormalities.
Background Pain, Number of Sensory Abnormalities and
Neuropathic Pain Grading
QST revealed that the numbers of sensory abnormalities did
not differ between the different neuropathic pain grades. This
observation challenges the hypothesis that the number of sensory
abnormalities is positively related to neuropathic pain grades using
the grading system [16].
In a study with 618 neuropathic- and non-neuropathic pain
patients, Dworkin and colleagues showed that pain intensity,
unpleasantness, quality, and spatial characteristics differed signif-
icantly between these groups [29]. In the present study we have
assessed the intensity of background pain prior to QST. There was
no correlation between background pain intensity and numbers of
somatosensory abnormalities in patients clinically diagnosed as
neuropathic pain or for the different grades of neuropathy.
Sensory testing in healthy subjects and patients using a
reaction time-sensitive ‘‘method of limits’’ procedure reported
poor reliability [30]. Therefore, its results are highly dependent
on the subjects’ motor abilities and attention [8]. In addition, the
majority of patients investigated (91%) used their regular
medication when the QST assessment took place which could
have even more influenced the assessments of WDT, CDT, HPT
and CPT and subsequently the sensory profiles detected. This is
not ideal, but it reflects the most common situation in which
QST testing is performed, clinically. Furthermore, all categories
of the neuropathic pain grading include patients with medication.
Apart from the ethical aspect of drug withdrawal leading to
increased pain, many neuropathic pain medications have long
elimination times and possible active metabolites, making drug
withdrawal prior to testing both unwarranted and unpractical.
In conclusion, our results indicate that there is a mismatch
between clinical neuropathic pain diagnoses and neuropathic pain
grading outcome. Only 60% of patients with clinically diagnosed
neuropathy were categorized as ‘definite’ and ‘probable’ neuro-
pathic pain patients. Even if such a stringent grading system may
provide advantages in selecting homogenous groups for clinical
research, numbers of somatosensory abnormalities within the
different certainties of neuropathic pain are remarkably similar.
The only significant finding to differentiate ‘‘true’’ neuropathic
pain from ‘‘unlikely’’ neuropathic pain was the difference in
somatosensory profiles, in particular with regard to the presence of
QST and Neuropathic Pain Grading
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the mixture of sensory gain and loss and only sensory loss.
Neuropathic pain grades as well as numbers of sensory abnor-
malities were not correlated with patients reported background
pain intensity.
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